It didn't take long for 2007 start-up Flexion Therapeutics to begin attracting venture financing and prospective pharma partners, all drawn to the Woburn, Mass.-based firm's unique business model aimed at giving deprioritized early stage compounds a second chance. (BioWorld Today) Read More
